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CHAPTER I 
 
INTRODUCTION 
 
Epilepsy 
Epilepsy is a common neurological disorder affecting 1% of the population worldwide, 
and is characterized by recurrent, unprovoked seizures resulting from synchronous 
neuronal discharges.1-4 An imbalance between excitatory and inhibitory 
neurotransmission is the neurophysiological hallmark of epilepsy. The term epilepsy 
encompasses a heterogeneous group of disorders that vary in severity, etiology and 
seizure type.   The classification and diagnosis of epilepsies is based on two features: the 
seizure type and the underlying cause.  In order to generate a consistent vocabulary that 
reflects the current state of our knowledge and understanding of epilepsies, in 2010 the 
International League Against Epilepsy revised the terminology for classifying seizures 
and etiology of epilepsy.   
 
Clinically, seizures can be classified into two categories: focal or generalized.  Focal 
seizures originate in a localized brain region that constitutes the seizure focus that is 
consistent from one seizure to another.  Features of focal seizures such as the impairment 
of consciousness or awareness, progression of seizure events and dyscognitive 
characteristics are descriptors used by clinicians for evaluating patients.  Generalized 
seizures, on the other hand, involve both hemispheres from the outset, rapidly engaging 
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bilaterally distributed networks and can be separated into several subcategories: tonic-
clonic, absence, myoclonic or others (less common).4-6  Tonic-clonic seizures are divided 
into two phases, the tonic phase where flexor and extensor muscles are simultaneously 
activated throughout the body resulting in a stiffening, followed by the clonic phase with 
a repetitive, rhythmic convulsion of muscles.  Absence seizures are characterized by a 
brief episode of unresponsiveness with loss of consciousness.  Myoclonic seizures are 
very brief muscle contractions involving the whole body or part of the body.   
 
The three terms genetic, structural/metabolic and unknown have been adopted for the 
etiological classification of epilepsies. Genetic epilepsies are the direct result of a known 
or presumed genetic defect in which seizures are the core symptom of the disorder.  In 
order to presume a genetic basis, either a gene and the molecular mechanisms should be 
identified or an appropriately designed family study should provide evidence of a genetic 
component.  Structural/metabolic epilepsies are a secondary result of a distinct other 
structural or metabolic condition.  Structural lesions associated with an increased risk of 
epilepsy may be acquired or of genetic origin.  However, these are distinct from “genetic 
epilepsies” because there is believed to be a separate disorder between the genetic defect 
and the epilepsy.  Lastly, the classification of unknown is used to reflect epilepsies in 
which the underlying cause is unknown and makes no assumptions regarding cause.6  
Albeit somewhat simple, these classifications have enabled clinicians to diagnose the 
epilepsy type and select the most effective treatment strategy for each patient.   
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Treatments of epilepsy 
The only existing cure for epilepsy is resective surgery for suitable patients and thus 
treatment of the majority of epilepsy patients with the currently available antiepileptic 
drugs (AEDs) is only symptomatic.  There are approximately twenty-four FDA approved 
antiepileptic drugs on the market with various mechanisms of action but most function to 
dampen neuronal signaling either by enhancing GABA-mediated inhibition or controlling 
excitability through actions on Na+ channels or T-type Ca+2 channels.7  Although many 
epilepsy patients achieve complete seizure control with current AEDs, these medications 
fail to control seizures in 30% of patients, highlighting the need not only for novel AEDs 
but also for research into the underlying molecular mechanisms of epilepsy that will 
contribute to our understanding of this debilitating disease.3 
  
Antiepileptic drug discovery  
Animal models of epilepsy have aided in our effort to understand the pathogenesis of 
epilepsy and have been instrumental for AED discovery.  The development of AEDs 
predominantly relies on the screening of test compounds for predictive activity against 
specific seizure types mimicked by acute seizure models, namely the maximal 
electroshock (MES) and pentylenetetrazole (PTZ) models.8  The MES seizure test was 
introduced in cats in 1937 and adapted for rodents in 1946.9,10  In the MES seizure model 
an electrical stimulus is administered either transcorneally or transauricularily to induce 
generalized tonic-clonic seizures.10  PTZ, a chemical convulsant, induces myoclonic and 
clonic convulsions.  Additional induced epilepsy models include kindling, kainate and 
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pilocarpine.  Amygdala kindling describes a process in which an electrical stimulus is 
administered to the amygdala via depth electrodes.  Repeated administration of the 
initially subconvulsive stimuli eventually induces seizures that increase in severity and 
duration.11  Kindling models are used to identify compounds that are predicted to be 
active against focal seizures in patients.  Both kainate and pilocarpine models of epilepsy 
exhibit spontaneous, recurrent seizures following the initial induction of status 
epilepticus with administration of either agent.12-14  The only genetic model of epilepsy 
being used for late-stage screening of AEDs is the GAERs rat which exhibits absence 
seizures.15  The 6-Hz psychomotor seizure model in which a prolonged electrical 
stimulus induces seizures has more recently been employed as a drug-resistant model in 
AED screens.16   All the models described, with the exception of the GAERs rat, 
represent induced seizure models occurring in non-epileptic brains and therefore do not 
accurately reflect the epilepsy process.  Since the introduction of these models and the 
establishment of the Anticonvulsant Screening Project of NIH/NINDS, numerous 
effective antiepileptic drugs have been generated.  However, this screening process, 
relatively unchanged since 1978 and reliant upon non-physiological models of epilepsy, 
has led to the stagnation of the development of new AEDs.  This is a significant problem 
as 30% of epilepsy patients remain without effective treatment options.3,8  The new 
generation of genetic epilepsy models which recapitulate spontaneous epilepsy in humans 
has been proposed as alternatives for the AED development and screening process.8   
 
Etiology of epilepsy 
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In addition to having utility in drug discovery, genetic models of epilepsy are being used 
to advance our knowledge regarding the pathology of epilepsy.  While disease and injury 
to the central nervous system are known to contribute to seizure susceptibility, the 
cellular and molecular mechanisms that underlie the pathogenesis of most epilepsies 
remain largely unknown (Figure 1.1).1  Previous work, however, has suggested the 
importance of genetic factors to the development of epilepsy.17  Although genetic 
epilepsies exhibit complex inheritance patterns, genetic mapping has identified mutations 
in single genes that are responsible for epilepsy in human patients.  All of the mutations 
that have been identified are molecular components of neuronal signaling, with mutations 
in voltage-gated sodium channels being the most prevalent.17   
 
 
 
Voltage-gated sodium channels 
Voltage-gated sodium channels are responsible for the initiation and propagation of 
action potentials in electrically excitable cells such as nerve, skeletal muscle and heart.  
Figure 1.1.  Proportion of cases of epilepsy by etiology (Adapted from Hauser et al, 1993).
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Voltage-gated sodium (Nav) channels are integral membrane proteins consisting of a 
pore-forming α-subunit (260 kD) complexed with one or more auxiliary β-subunits (33-
40 kD) (Figure 1.2).18-21  Nine genes encoding distinct α-subunits and four encoding β-
subunits have been identified in the human genome and the isoforms exhibit variable 
tissue expression patterns (Table 1.1).21  The α-subunit is composed of four structurally 
homologous domains (D1-D4) each containing six transmembrane segments (S1-S6).  
When the α-subunit adopts its three-dimensional structure within the membrane, it 
creates an ion-conducting pore with ion selectivity and permeation controlled by the S5-
S6 pore loop of each domain.  The S4 segment of each domain contains basic amino 
acids (arginine or lysine) at every third position and functions as a voltage-sensor. 18-20 
The β-subunits are single transmembrane proteins that modify the kinetics and voltage-
dependence of gating of the α-subunit.  Accessory β-subunits are also involved in channel 
localization and interact with other signaling molecules and the cytoskeleton making 
them an essential component of the Nav channel macromolecular complex.21,22 
 
 
 
 
Figure 1.2.  Schematic representation of a single voltage-gated sodium channel α-subunit and 
auxiliary β-subunit. 
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Given the importance of Nav channels to action potential generation and neuronal 
signaling, it is not surprising that more than 800 mutations in Nav channels have been 
identified in association with a range of clinically diverse epilepsies.20,21,23  Mutations 
within Nav1.1 constitute the greatest number of mutations identified; however, mutations 
within Nav1.2, Nav1.3, Nav1.6 and the β1 subunit have also been described.17,24  Utilizing 
whole-cell electrophysiology, researchers have been able to characterize the biophysical 
properties of these disease-associated mutant channels.  High resolution functional 
characterization of several mutations has provided insight on the molecular mechanisms 
by which voltage-gated sodium channel dysfunction contributes to epileptogenesis.  
Interestingly, the mutations identified exhibit altered biophysical properties 
representative of both gain-of-function and loss-of-function phenotypes.   
 
Table 1.1.  
Mammalian voltage-gated sodium channel genes 
Gene Protein Tissue Expression 
SCN1A Nav1.1 CNS, PNS, cardiac muscle* 
SCN2A Nav1.2 CNS, PNS 
SCN3A Nav1.3 CNS, PNS 
SCN4A Nav1.4 skeletal muscle  
SCN5A Nav1.5 cardiac muscle, skeletal muscle* 
SCN8A Nav1.6 CNS, PNS, cardiac muscle* 
SCN9A Nav1.7 PNS 
SCN10A Nav1.8 PNS 
SCN11A Nav1.9 PNS 
 
 
 
 
CNS, central nervous system; PNS, peripheral nervous system; 
*minor expression (Adapted from Meisler and Kearney, 2005). 
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Gain-of-function mutations within Nav channels are believed to enhance neuronal 
excitability thereby increasing seizure susceptibility.  Functional studies of epilepsy-
associated mutations have shown biophysical abnormalities in both activation and 
inactivation parameters that are predicted to promote excitability.  The SCN1A mutation 
W1204R exhibits a hyperpolarized shift in the voltage-dependence of activation which is 
consistent with hyperexcitability.25-27  A depolarized shift in the voltage-dependence of 
inactivation as observed with the mutations T875M and D1866Y of SCN1A represents 
gain-of-function in channel activity.26,28,29  An increased rate in the recovery from 
inactivation would result in a greater number of channels available to reactivate in 
response to depolarization.  This biophysical defect is observed with the SCN1A mutation 
D188V.30  A common gain-of-function biophysical defect is impaired channel 
inactivation leading to increased persistent sodium current.26,31  For example, the SCN1A 
epilepsy-associated mutation R1648H exhibits a level of persistent sodium current that is 
~4.5% of peak current compared to less than 1% for the wildtype channel.31   Persistent 
sodium current is hypothesized to reduce the threshold for action potential firing, directly 
resulting in neuronal hyperexcitability.   
 
Because epilepsy is a disorder that reflects neuronal hyperexcitability, the relationship 
between epilepsy and gain-of-function mutations in Nav channels consistent with cellular 
excitability seems rather intuitive.  Functional studies, however, have revealed loss-of-
function properties in disease-associated mutants.  The first sodium channel mutation 
identified in association with epilepsy was C121W in the β1 subunit gene SCN1B which 
resulted in impaired modulation of the associated subunit.32  Depolarizing shifts in the 
9 
 
voltage-dependence of activation and reduced sodium current density have been observed 
in functional studies and are consistent with loss-of-function.31,33,34  Other mutations have 
been described as nonfunctional resulting from a failure to conduct sodium ions or 
defects in protein trafficking reducing cell surface expression.35,36  In Dravet syndrome, a 
rare epileptic encephalopathy, more than half of the identified mutations in SCN1A 
introduce frameshifts or premature stop codons suggesting that haploinsufficiency of 
SCN1A is pathogenic.24,37,38  While initially it may seem counter-intuitive that 
haploinsufficiency of SCN1A would cause epilepsy, its regional expression pattern may 
shed light on the mechanism by which loss-of-function leads to hyperexcitability rather 
than hypoexcitability.  Studies have shown that distribution of SCN1A across brain 
regions is heterogeneous.  Within the hippocampus, SCN1A expression is largely 
dependent upon cell type.  Pyramidal neurons express negligible levels of SCN1A, 
whereas, interneurons express significantly higher SCN1A levels.39  The preferential 
expression of SCN1A within interneuron populations suggests that interneuron activity 
would be affected by loss-of-function of SCN1A to a greater extent than would pyramidal 
neurons.  Impaired function of GABAergic interneurons resulting from loss of SCN1A 
function would upset the balance between inhibitory and excitatory neurotransmission, 
tipping the scale toward network hyperexcitability.   
 
Functional characterization of mutant alleles has allowed researchers to correlate 
genotype-phenotype relationships with the molecular mechanisms that underlie genetic 
epilepsies.  Along with the functional characterization of epilepsy-associated mutations 
has come the generation of mouse models harboring patient mutations.  Genetic mouse 
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models of epilepsy have been excellent tools for testing specific disease mechanisms 
thereby furthering our understanding of the pathophysiology of epilepsy and for 
evaluating targeted therapeutics.  Information gained from both the functional 
characterization of mutants and the use of mouse models has been instrumental for 
directing the design of desperately needed novel therapies, with the ultimate goal of 
developing individualized treatments tailored to each patient mutation.  Two mouse 
models of epilepsy are described in greater detail below.   
 
Scn2aQ54 mouse model of epilepsy 
A genetically engineered mouse line, Scn2aQ54 (Tg(Eno2-Scn2a1*)Q54Mm), expresses a 
transgene encoding an inactivation impaired neuronal Nav1.2 channel.  The mutation, 
consisting of a substitution of glutamine for three adjacent residues, is located in an 
evolutionarily conserved region in the linker between transmembrane segments 4 and 5 in 
domain 2 (GAL879-881QQQ) (Figure 1.3A).  In heterologous expression systems, this 
mutation results in abnormal inactivation with increased persistent sodium current when 
compared to wildtype channels (Figure 1.3 B-C).  Mice expressing the Scn2aQ54 
transgene driven by the neuron-specific enolase promoter exhibit a severe epilepsy 
phenotype that is characterized by frequent partial seizures corresponding to EEG 
evidence of a seizure focus in the hippocampus.  These short duration partial seizures 
begin in early life then progress to secondarily generalized seizures, status epilepticus and 
premature death.  Epilepsy in Scn2aQ54 mice is correlated with persistent sodium current 
in hippocampal pyramidal neurons. These animals also show histopathological changes 
such as CA1-CA3 and hilar cell loss, gliosis and mossy fiber sprouting in the 
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hippocampus which also occur in human epilepsy patients.  Transgenic overexpression of 
wildtype Nav1.2 does not lead to a seizure disorder or reduced lifespan. 40  
 
 
 
 
 
 
The severity of the seizure phenotype observed in Scn2aQ54 mice is influenced by the 
genetic background.  Scn2aQ54 mice congenic on strain C57BL/6J (B6.Q54) have a 
seizure onset around 2 months of age with only a 20% incidence at 6 months of age.  A 
cross between hemizygous B6.Q54 males with SJL/J females yields transgenic 
 
Figure 1.3.  Scn2aQ54 mouse model of epilepsy.  (A) NaV1.2 mutation (Kearney et al, 2001). 
(B) Representative trace of sodium current from wildtype Nav1.2 (black trace) or Nav1.2 
GAL879-881QQQ (red trace).  (C) Summary data for persistent sodium current expressed as 
% peak current recorded from tsA201 cells - Chris Thompson, PhD. 
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heterozygotes on an F1 background (F1.Q54).  Seizure onset is around 3 weeks of age in 
F1.Q54 mice with 100% incidence at 6 months.  F1.Q54 mice exhibit a higher seizure 
incidence, increased seizure severity and reduced lifespan when compared to B6.Q54 
mice.41  Within the F1.Q54 population, female mice exhibit a significantly greater 
frequency of seizures than males (Figure 1.4).  The Scn2aQ54 mouse, which models 
mesial temporal lobe epilepsy, provides an excellent model to investigate therapies that 
would prove effective in patients carrying gain-of-function mutations with persistent 
sodium current.   
 
 
 
 
Scn1a+/- mouse model of epilepsy 
Loss-of-function SCN1A mutations have been modeled by Scn1a knockout mice, which 
exhibit a severe epilepsy phenotype mimicking Dravet syndrome.  Two groups have 
generated heterozygous Scn1a knockout (Scn1a+/-) mice and described consistent 
 
Figure 1.4.  Scn2aQ54 mice exhibit sex differences in seizure frequency.  Female F1.Q54 mice 
exhibit a greater number of seizures than male mice during a 30 minute observation period  
(** p < 0.005).  
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phenotypes.42-44  The first Scn1a+/- mouse that was generated by targeted deletion of exon 
26 of Scn1a (Scn1atm1Wac) was described by the Catterall group in 2006. Scn1a+/- mice are 
reported to exhibit severe, spontaneous generalized tonic-clonic seizures beginning 
around 2-3 weeks of age, have a reduced seizure threshold and reduced lifespan.  
Electophysiological recordings of hippocampal interneurons isolated from Scn1a+/- mice 
show a reduction in sodium current density, with no changes in the voltage-dependence 
of activation or inactivation.  Shortly after the introduction of the Catterall Scn1a+/- 
mouse, a knock-in mouse line carrying a premature stop codon, R1407X, in Scn1a 
(Scn1atm1Kzy) was generated and characterized by the Yamakawa group.39  The Scn1aRX/+ 
mouse also models Dravet syndrome with recurrent, spontaneous seizures and premature 
death.  The epilepsy phenotype of Dravet syndrome mice is strongly dependent on 
genetic background. The Kearney group generated Scn1a+/- mice on the 129S6/SvEvTac 
background  (129.Scn1a+/-) by replacing exon 1 with a neomycin selection cassette 
(Scn1atm1Kea) and confirmed reduced Nav1.1 expression to ~50% of wildtype levels in 
brain (Figure 1.5).  Heterozygous 129.Scn1a+/- mice do not exhibit overt seizures and 
sporadic death is rare (<10% at 12 weeks).  However, when heterozygous 129.Scn1a+/- 
mice are crossed to the C57BL/6J background, F1.Scn1a+/- mice are generated.  On the 
mixed genetic background, F1.Scn1a+/- mice have frequent seizures with a high incidence 
of spontaneous death with only 30% survival to 12 weeks  (Figure 1.5 C).  Results 
garnered from Dravet syndrome mice have led to the prevailing sentiment that impaired 
GABA-mediated inhibition is primarily responsible for seizure generation and 
epileptogenesis in patients exhibiting loss-of-function SCN1A mutations. 
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Figure 1.5. Scn1a+/- mouse model of epilepsy.  (A) Exon 1 containing the translation start site 
was replaced by a selection cassette by homologous recombination in ES cells. The targeting 
vector contained the pGK-puR-Δtk-EM7-NeoR selection cassette flanked by lox sites 
(triangles), a 6.1 kb 5’ homology arm and a 4.8 kb 3’ homology arm. The diphtheria toxin 
cDNA (DT-A) cassette was located outside of the targeting arm for negative selection against 
random integrations. (B) Western blot of brain membrane proteins with a Nav1.1 and β-tubulin 
antibody. (C) Survival of F1.Scn1a+/- mice is significantly reduced compared to 129.Scn1a+/- 
mice (Miller et al, 2014). 
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Specific Aim 1:  To determine whether transgenic expression of Nav1.1 in 
GABAergic neurons would rescue the epilepsy phenotype of Scn1a+/- mice. 
We hypothesized that restoration of SCN1A selectively in GABAergic interneurons 
would attenuate or prevent the epilepsy phenotype in Scn1a+/- mice.  To test this 
hypothesis, we generated transgenic mice in which human SCN1A is expressed 
selectively in GABAergic neurons using a Gad67-specific promoter (Gad67-SCN1A).  
We crossed Scn1a+/- mice with Gad67-SCN1A transgenic mice to generate a subset of 
offspring that have one wildtype allele, the knockout allele and one copy of the Gad67-
SCN1A transgene expressed selectively in inhibitory neurons.  We monitored long term 
survival of combined knockout/transgenic animals (Scn1a+/- :: SCN1ATg/+) to evaluate 
whether the mortality associated with Scn1a+/- mice could be ameliorated by restoring 
sodium channel expression in interneurons.  Results from these studies provided insight 
into the potential success of using a genetic approach for the treatment of Dravet 
syndrome, or inform the development of pharmacological agents that achieve the same 
degree of restored sodium current.  
 
Specific Aim 2: To determine whether preferential inhibition of persistent sodium 
current would be antiepileptic in Scn2aQ54 mice. 
Increased persistent sodium current has been implicated as a contributor to the 
pathogenesis of epilepsy.  We hypothesized that a drug capable of preferentially 
suppressing persistent sodium current would be an effective antiepileptic drug.  
Ranolazine, an FDA-approved drug for the treatment of angina pectoris, and the recently 
described novel compound, GS-458967 (GS967), selectively inhibit persistent sodium 
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current.  We examined the antiepileptic potential of ranolazine and GS967 in the 
genetically engineered Scn2aQ54 mouse model of epilepsy. We tested whether acute 
treatment with ranolazine or GS967 would reduce seizure frequency of Scn2aQ54 mice.  
We also evaluated whether persistent sodium current inhibitors improved survival of 
Scn2aQ54 mice.  Results from these experiments indicated that preferential inhibition of 
persistent sodium current represents a novel targeted antiepileptic drug strategy for 
treating genetic epilepsies associated with gain-of-function voltage-gated sodium channel 
mutations. 
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CHAPTER II 
 
GENERATION OF A TRANSGENIC MOUSE LINE SELECTIVELY EXPRESSING 
SCN1A IN GABAERGIC NEURONS FOR RESCUING DRAVET SYNDROME 
 
 
INTRODUCTION 
Dravet syndrome, also known as severe myoclonic epilepsy of infancy (SMEI), is a 
catastrophic pediatric epileptic encephalopathy.  Children with Dravet syndrome 
generally exhibit normal development during the first year of life but then develop 
seizures often in association with fever, with eventual progression to spontaneous, 
recurrent seizures and status epilepticus.  Following the onset of seizures, Dravet 
syndrome patients develop severe comorbidities including cognitive impairment, ataxia 
and psychomotor dysfunction.45,46  Because these children respond poorly to available 
antiepileptic drugs, there is unfavorable long-term survival.46,47  More than 70% of 
Dravet syndrome patients have de novo heterozygous mutations in the SCN1A gene 
encoding the voltage-gated sodium channel α1 subunit (Nav1.1).48,49  Heterozygous 
missense and truncation mutations suggest haploinsufficiency of SCN1A as the genetic 
mechanism of Dravet syndrome. 
 
Recent studies have demonstrated that heterozygous Scn1a knockout (Scn1a+/-) mice 
recapitulate the phenotype of Dravet syndrome.  Scn1a+/- mice display spontaneous 
seizures and premature lethality.  They also exhibit a reduced threshold for both 
hyperthermia- and flurothyl-induced seizures as well as cognitive and motor 
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impairments.42-44  Electrophysiological studies in dissociated hippocampal neurons from 
Scn1a+/-  mice have shown a reduced sodium current density and impaired excitability in 
GABAergic interneurons suggesting that impaired GABA-mediated inhibition underlies 
the pathophysiology of Dravet syndrome.42,44  To further support this interneuron 
hypothesis, Cheah et. al. generated a conditional deletion mouse model in which Nav1.1 
was selectively deleted from forebrain GABAergic interneurons using a Cre-Lox system.  
Deletion of Scn1a selectively from GABAergic interneurons is sufficient to cause 
epilepsy as the seizure and premature death phenotypes observed in Dravet syndrome are 
mimicked in this conditional deletion model.50   
 
In this study, we generated a transgenic mouse line in which human SCN1A is expressed 
selectively in GABAergic neurons (Gad67-SCN1A).  We have used this Gad67-SCN1A 
mouse line to directly test the hypothesis that the epilepsy phenotype in Dravet syndrome 
mice (Scn1a+/-) can be rescued by restoring sodium channel expression in GABAergic 
neurons. 
 
METHODS 
Animals 
All animal care and experimental procedures were approved by the Vanderbilt University 
Institutional Animal Care and Use Committee.  Mice were group-housed in a pathogen 
free mouse facility under standard laboratory conditions (12-hr light/dark cycle) and had 
access to food and water ad libitum.  Scn1a+/- mice were generated as previously 
described and are maintained as a congenic line on the 129S6/SvEvTac background 
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(129.Scn1a+/-).43  Each Gad67-SCN1A transgenic founder was crossed to strain 
C57BL/6J for at least seven generations to generate an independent line incipient 
congenic on the C57BL/6J background (B6.SCN1ATg/+).  Mice used for experiments were 
from the eighth (N8) or greater backcross generation.  Generation of F1 combined 
knockout/transgenic mice (Scn1a+/- :: SCN1ATg/+) was carried out by crossing 
129.Scn1a+/- mice with B6.SCN1ATg/+ hemizygous mice.  Mice were tail biopsied in the 
second postnatal week, and DNA was prepared from tail tissue using the Gentra Puregene 
Mouse tail kit according to the manufacturer’s instructions (Qiagen, Valencia, CA).  
Genotyping of Scn1a+/- mice was performed as previously described.43  Genotyping of 
the Gad67-SCN1A transgene was performed by multiplex PCR with primers A (5’ CTC 
CTC TTC TGC CCG TTC AC 3’), B (5’ ATA AGC ACG GGT AGT GAAG 3’) and C 
(5’ GAA GAT GGC CTT CCC TTT ATTC 3’).  Amplification was initiated by 
denaturation for 2 minutes at 94 ͦ C, followed by 33 cycles of 30s at 94 ͦ C, 30s at 58 ͦ C and 
1 minute at 72 ͦ C.  PCR products were electrophoresed on 1.5% agarose gels and 
visualized with ethidium bromide.    
 
Real-time quantitative PCR 
Genomic DNA was isolated from tail biopsies by proteinase K digestion, phenol/ 
chloroform extraction and ethanol precipitation.  DNA was resuspended in TE at a 
concentration of 40 ng/µL.  Real-time quantitative PCR was performed using a Taqman 
Gene Expression Assay for transferrin receptor (Tfrc) (Applied Biosystems, Foster City, 
CA) and a custom primer and probe set for Gad67-SCN1A to determine transgene copy 
number. The custom Taqman assay for Gad67-SCN1A included primers D (5’ AGA CCC 
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CAA ACC GGT ATC ATC 3’) and E (5’ AGC TGT CAG GTC CTG GTG GTA 3’) and 
probe (5’6FAM-TGC TCC ATG CGG CCG CC-MGBNFQ 3’).  Real-time PCR was 
performed in triplicate (45 cycles) using Taqman Fast Universal PCR Master Mix on a 
7900HT Fast Real-Time PCR System with Sequence Detection System 2.2 software 
(Applied Biosystems).  All assays lacked detectable signal in no template controls.  Copy 
number was estimated using a standard curve prepared by spiking C57BL/6J genomic 
DNA with Gad67-SCN1A plasmid DNA. 
 
Western blot analysis 
Western blot analysis was performed on brain membrane protein preparations that were 
isolated as previously described.51  Brain membrane proteins were subjected to 7.5% 
SDS-PAGE and transferred to a PVDF membrane.  Proteins were detected with primary 
antibodies directed against the HA-epitope (mouse, anti-HA.11 clone 16B12, 1:500, 
Covance) or the loading control β-tubulin (mouse, anti- β-tubulin clone TUB2.1, 1:5000, 
Sigma-Aldrich).  Immunoreactive bands were detected using horseradish peroxidase-
conjugated secondary antibody directed against the primary antibody (goat, anti-mouse, 
1:10,000, Santa Cruz) coupled with ECL Plus reagent and then imaged with 
hypersensitive ECL film.  Densitometry using NIH ImageJ was performed and band 
intensity of HA-epitope was normalized to that of β-tubulin. 
 
Survival Analysis 
129.Scn1a+/- females were crossed with B6.SCN1ATg/+ hemizygous males to generate F1 
generation mice for a survival study.  Survival was monitored until 8 weeks of age.  
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Littermates were used as controls.  Statistical comparisons were made using the Cox 
proportional hazards model and p < 0.05 was considered statistically significant.   
 
Seizure threshold testing 
Flurothyl (2,2,2-trifluroethylether) was used as previously described to induce seizures in 
P21-24 mice.52  Seizure threshold was determined by measuring latency to the 
generalized tonic-clonic seizure which is characterized by loss of posture and convulsions 
on the entire body.  All genotypes generated from crossing 129.Scn1a+/- and 
B6.SCN1ATg/+ mice were used for seizure threshold testing.  Statistical comparisons were 
made using one-way ANOVA followed by Tukey’s post-test and p < 0.05 was 
considered statistically significant.   
 
RESULTS 
Generation of Gad67-SCN1A mouse lines 
We generated a DNA plasmid containing the human SCN1A transgene.  The transgene 
cassette includes SCN1A under control of the Gad67 promoter and an IRES element 
preceding the fluorescent Venus (Figure 2.1).  The ~2.8 kb promoter fragment from the 
murine Gad1 gene includes 1.2 kb of flanking sequence, exon 1, intron 1 and 44 bp of 
exon 2.53  The 6 kb human SCN1A cDNA construct contains 3 repeats of the HA-epitope 
at the C-terminus.  The transgene construct was cloned into a vector containing piggyBac 
transposon inverted repeats.  This transposon-bearing DNA plasmid and RNA encoding a 
transposase were microinjected into (C57BL/6J x DBA/2J)F1 fertilized oocytes in the 
Vanderbilt University Transgenic Mouse Core.  Qualitatively, Gad67-SCN1A 
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hemizygous (SCN1ATg/+) mice have no overt phenotype and are indistinguishable from 
wildtype littermates as they survive and breed normally.  Further characterization of 
Gad67-SCN1A mice is presented below. 
 
 
 
Gad67-SCN1A transgenic mice 
Three independent lines of mice each carrying an independent insertion of the wildtype 
human SCN1A transgene were generated.  Transgenic mice were identified and the 
number of inserted transgene copies was estimated using real-time quantitative PCR on 
genomic DNA.  A benefit of using the piggyBac transposon system is that transgene 
integration is highly efficient and it prevents the integration of concatamers.54  The high 
efficiency of the piggyBac system, however, allows for multiple insertions of the 
transgene at different locations within the genome.  Transgenic mice containing two or 
fewer copies of the transgene were backcrossed to C57BL/6J mice.  Transgene copy 
number was calculated on the N2 generation mice and those with a single transgene copy 
were selected as transgenic founders (Table 2.1). 
 
 
Figure 2.1. Structure of the Gad67-SCN1A transgene.  Primers are indicated with half arrows.  
Primers A and C were used for genotyping.  Primers D and E and *, probe were used for 
quantitative PCR. 
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Table 2.1.  
Gad67-SCN1A transgenic lines   
Construct Line Copy Number Expression 
Gad67-SCN1A 4.7 1.2  low 
 9.4 1.0 moderate 
 13.18 1.1 high  
    
Gad67-SCN1A-
R1648C 1.39 0.7 not done 
 2.15 0.8 not done 
 
 
Western blot analysis was used to determine relative transgene expression in whole brain 
tissue.  Varying levels of the SCN1A transcript was detected across the three transgenic 
lines, with line 4.7 displaying low expression approximately 2-3 fold less abundant than 
line 13.18 (Figure 2.2). 
 
 
 
 
 
 
 
Figure 2.2. Western blot analysis of brain membrane proteins from Gad67-SCN1A transgenic 
lines.  Representative blot for two-three biological replicates is shown for wildtype (WT) mice 
and mice from each of the transgenic lines.  The SCN1A transgene was detected by antibodies 
directed against the HA-epitope.  β-tubulin was used as a loading control.  Lane 6 was mis-
loaded and excluded from analysis.  
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In addition to the Gad67-SCN1A transgenic lines, we generated a transgenic line in which 
the Dravet syndrome associated SCN1A mutation, R1648C, is expressed selectively in 
GABAergic neurons (Gad67-SCN1A-R1648C).  Two independent lines of Gad67-
SCN1A-R1648C hemizygous mice were generated (Table 2.1).  Qualitatively, transgenic 
mice expressing mutant SCN1A selectively in GABAergic neurons have no overt 
phenotype and a normal lifespan. 
 
Survival analysis of combined knockout/transgenic animals (Scn1a+/- :: SCN1ATg/+) 
Scn1a+/- mice have a significantly reduced lifespan compared to wildtype littermates with 
only ~25% surviving to 8 weeks of age (Figure 2.3).  In order to directly test the 
hypothesis that the Dravet syndrome phenotype of Scn1a+/- mice can be rescued by 
restoring sodium channel expression selectively in inhibitory neurons, we generated 
combined knockout/transgenic animals (Scn1a+/- :: SCN1ATg/+) with each of the Gad67-
SCN1A transgenic lines and monitored survival of all generated genotypes for 8 weeks.  
Normal survival of Scn1a+/- mice was not rescued by restoration of GABAergic SCN1A 
(Figure 2.3).  Gad67-SCN1A transgenic line 9.4 had a trend of partial rescue but was not 
statistically significant ( p = 0.059). 
 
Latency to flurothyl-induced seizures 
Scn1a+/- mice exhibit a shorter latency (193 ± 21 sec) to first generalized tonic-clonic 
seizures following exposure to the volatile convulsant flurothyl compared to wildtype 
(269 ± 8 sec, p < 0.05) littermates.  Neither Gad67-SCN1A transgenic line (9.4 or 13.18) 
was able to rescue the flurothyl-induced seizure threshold of Scn1a+/- mice.   
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DISCUSSION 
In an effort to determine the neurophysiological mechanism responsible for Dravet 
syndrome, mouse models that recapitulate the disease phenotype have been generated by 
targeted deletion of mouse Scn1a and knock-in of a human SCN1A truncation mutation 
associated with Dravet syndrome.39,42,43  Dravet syndrome mice exhibit spontaneous 
seizures, premature death and a reduced threshold for induced seizures.  
Electrophysiological recordings from Scn1a+/- mouse hippocampal neurons have shown 
reduced sodium current density and excitability of GABAergic interneurons, which is 
hypothesized to be the basis for Dravet syndrome.  More recent studies have generated 
mice in which SCN1A has been conditionally knocked-out of inhibitory neuron 
populations.  Conditional deletion of Scn1a from interneurons was sufficient to cause 
 
Figure 2.3. Survival curves of combined knockout/ transgenic mice (Scn1a+/- :: SCN1ATg/+). 
Scn1a+/- mice were not rescued by transgenic expression of SCN1A selectively in inhibitory 
neurons. Transgenic line is noted in parenthesis, with n = 13-55 per group.  Survival 
difference between groups was not significant; Cox proportional hazards model. 
26 
 
epilepsy and lethality in mice.50  Results from these mouse models support the 
interneuron-hypothesis of epileptogenesis in Dravet syndrome.   
 
We hypothesized that restoration of SCN1A selectively in interneurons would attenuate or 
prevent the epilepsy phenotype in Dravet syndrome mice, and generated a Gad67-SCN1A 
transgenic mouse line that expresses human SCN1A selectively in GABAergic neurons.  
Experiments with combined knockout/transgenic mice are still ongoing.  Preliminary 
experiments, however, show that selective expression of SCN1A in inhibitory neurons of 
Scn1a+/- mice was not able to rescue the Dravet syndrome phenotype.  While one Gad67-
SCN1A line (9.4) showed a trend of partial rescue for the survival of Scn1a+/- mice, the 
improvement was not statistically significant.   The survival study was greatly under-
powered (power = 0.4) to observe partial rescue as we had assumed full rescue during 
experimental design.  In order to achieve statistical significance, sample size would need 
to increase 3-fold. Additionally, no improvement was observed with either Gad67-
SCN1A transgenic line for the reduced threshold to flurothyl-induced seizures in Scn1a+/- 
mice.  Our preliminary results are not entirely consistent with the idea of an interneuron-
only defect in Dravet syndrome as the cause of premature mortality and suggest the 
possibility of an additional mechanism.  This is consistent with recent work proposing 
that a combination of both inhibitory interneuron and excitatory pyramidal neuron 
dysfunction contributes to the lethality of Dravet syndrome in mice.  Studies in acutely 
dissociated hippocampal neurons isolated from Scn1a+/- mice revealed increased sodium 
current density and a hyperpolarized shift in the voltage-dependence of activation of 
pyramidal neurons compared to wildtype littermates in addition to reduced sodium 
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current density in inhibitory GABAergic interneurons.44  Additionally, increased sodium 
current density was observed in pyramidal neurons differentiated from Dravet syndrome 
patient-derived iPSCs.55  This idea of a hyperexcitable component to the pathology of 
Dravet syndrome is further explored in Chapter III. 
 
We were not able to attenuate or prevent the premature death phenotype of Scn1a+/- mice 
by restoring SCN1A selectively in GABAergic neurons using Gad67-SCN1A transgenic 
mouse lines.  We have suggested that the failure of the Gad67-SCN1A mouse lines to 
rescue survival in Scn1a+/- mice may be because additional mechanisms underlie the 
pathophysiology of Dravet syndrome rather than only a loss of GABA-mediated 
inhibition.  Other possible reasons for this failure may relate to the transgene integration 
site into the genome, or the cellular localization of the transgene product.  If the transgene 
inserted within an essential gene, this could confound our results.  It is also possible that 
we failed to observe rescue due to the targeting of all Gad67 positive (Gad67+) neurons.  
While Gad67 expression marks GABA producing neurons, GABAergic lineages are 
divided into interneuron populations that project locally and neuron populations with 
long-range projections.  By using the Gad67 promoter to drive sodium channel 
expression, the rescue strategy also includes Gad67+ non-interneurons which may be 
affecting rescue.  Additionally, it is known that interneurons innervate and control other 
interneurons.56,57  Because our rescue strategy for restoring SCN1A expression included 
all Gad67+ neurons, it is possible that interneuron/interneuron interactions became 
overactive, leading to a resultant hyperexcitability of the hippocampus.  To address these 
concerns, future experiments should restore SCN1A expression in specific interneuron 
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subpopulations such as parvalbumin- or somatostatin-positive inhibitory interneurons.  
Another possibility explaining why the Gad67-SCN1A transgenic lines did not rescue the 
phenotype could be because we either restored too much or failed to achieve adequate 
sodium channel expression.  To address this concern, we propose electrophysiological 
experiments to examine sodium current density in acutely dissociated hippocampal 
interneurons from each of the transgenic lines because we found that they have varying 
levels of transgene expression. 
 
In some cases of Dravet syndrome, conventional sodium channel-blocking antiepileptic 
drugs (AEDs) such as lamotrigine have been shown to paradoxically worsen the 
disease.58  There are currently no models in which AED-induced exacerbation of epilepsy 
has been replicated.  In vitro, our lab has shown that lamotrigine treatment increases cell 
surface expression of the Dravet syndrome associated SCN1A mutation R1648C.35  
Functional characterization of SCN1A-R1648C has revealed both gain- and loss-of-
function phenotypes.  SCN1A-R1648C exhibits persistent sodium current in addition to an 
overall reduced sodium current density resulting from impaired cell surface 
trafficking.31,35  Lamotrigine treatment rescues cell surface trafficking of SCN1A-R1648C 
which evokes increased persistent sodium current that could exacerbate seizure 
generation.  In order to examine the underlying mechanism responsible for the worsening 
phenotype of Dravet syndrome patients treated with certain AEDs, we generated a 
transgenic mouse line in which SCN1A-R1648C was expressed selectively in GABAergic 
neurons (Gad67-SCN1A-R1648C).  We will use this mouse line to investigate trafficking 
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rescue of a dysfunctional channel as a potential mechanism for the exacerbation of the 
Dravet syndrome phenotype by some AEDs.  
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CHAPTER III 
 
PREFERENTIAL INHIBITION OF PERSISTENT SODIUM CURRENT IS AN 
EFFECTIVE ANTIEPILEPTIC DRUG MECHANISM 
 
 
INTRODUCTION 
Epilepsy is a common neurological disorder characterized by recurrent, spontaneous 
seizures.1-3 Antiepileptic drugs (AEDs) are the mainstay of treatment for most patients 
and several mechanistically distinct classes of agents are available. Unfortunately, 30% 
of persons affected by epilepsy fail to achieve adequate seizure control with currently 
available pharmaceuticals suggesting the need for new AEDs.3  
 
Many widely used and successful AEDs target voltage-gated sodium (Nav) channels, 
typically by mechanisms resulting in use-dependent block of transient sodium current.  
Persistent sodium current, a small non-inactivating component of overall current carried 
by NaV channels, may be another potential target for AED action. Neurons in several 
brain regions exhibit persistent sodium current and this activity may help amplify 
subthreshold synaptic potentials and facilitate repetitive firing.59 Further, increased 
persistent sodium current is an observed feature of several heterologously expressed 
mutant human Nav channels associated with familial epilepsy syndromes such as genetic 
epilepsy with febrile seizures plus (GEFS+).60   Ranolazine is an FDA-approved drug for 
the treatment of angina pectoris arising from coronary insufficiency and acts by 
preferentially inhibiting persistent sodium current in heart.  We previously reported that 
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ranolazine can suppress persistent current generated by several human NaV1.1 mutations 
associated with genetic epilepsies or familial hemiplegic migraine.61  Ranolazine has also 
been shown to reduce action potential firing and epileptiform activity in cultured 
neurons.62  Whether preferential suppression of persistent sodium current would be 
antiepileptic in vivo is unknown. 
 
The genetically engineered mouse line, Scn2aQ54, expresses a transgene encoding an 
inactivation-impaired neuronal NaV1.2 channel. Mice expressing the Scn2aQ54 transgene 
exhibit a severe epilepsy phenotype that is characterized by short-duration partial seizures 
beginning in early life that then progress to secondarily generalized seizures, status 
epilepticus and premature death.40,41  Epilepsy in Scn2aQ54 mice is correlated with 
increased persistent sodium current in hippocampal neurons. These animals also exhibit 
histopathologic changes in the hippocampus, including hilar neuron loss and mossy fiber 
sprouting that also occur in chronic human epilepsy. This animal model provides an 
excellent opportunity to test the efficacy of drugs targeting persistent sodium current.  We 
hypothesized that preferential inhibition of persistent sodium current would eliminate 
sodium channel dysfunction and exert an antiepileptic effect in Scn2aQ54 mice. 
 
Heterozygous Scn1a knockout (Scn1a+/-) mice exhibit a severe epilepsy phenotype with 
spontaneous seizures and premature death that models Dravet syndrome in humans.  
Heterozygous loss of Scn1a impairs GABA-mediated inhibition because of a reduced 
sodium current density and neuronal excitability in GABAergic interneurons.42-44  Due to 
the haploinsufficiency of SCN1A, it should come as no surprise that conventional 
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voltage-gated sodium channel blockers are ineffective in patients with Dravet syndrome.   
In some cases, lamotrigine has even been shown to cause a paradoxical worsening of the 
disease.58   We hypothesized that Scn1a+/- mice would either be resistant to or would 
exhibit seizure aggravation with drugs targeting persistent sodium current.   
 
In this study, we investigated the antiepileptic effect of preferential persistent sodium 
current inhibition using ranolazine and the recently described novel compound, 
GS967.63,64 We observed that both ranolazine and GS967 reduced seizure frequency in 
Scn2aQ54 mice, and GS967 inhibited spontaneous action potential firing in neurons 
isolated from Scn2aQ54 mice. GS967 was also effective at protecting against seizures in 
the maximal electroshock (MES) model.  Additionally, we found that long-term 
treatment with GS967 greatly improved survival, prevented hilar neuron loss and 
suppressed the development of mossy fiber sprouting in Scn2aQ54 mice.  Surprisingly, we 
also found that survival of Scn1a+/- mice was significantly improved with long-term 
treatment of GS967. 
 
MATERIALS AND METHODS 
Animals 
All animal care and experimental procedures were approved by the Vanderbilt University 
Institutional Animal Care and Use Committee.  Mice were group-housed in a pathogen-
free mouse facility under standard laboratory conditions (12-h light/dark cycle).  Mice 
had access to food and water ad libitum, except during experiments.  Scn2aQ54 transgenic 
mice were generated as previously described and are maintained as a congenic line on the 
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C57BL/6J background (B6.Q54) by continued backcrossing of B6.Q54 hemizygous 
males to C57BL/6J females.40  For experiments, F1 generation Scn2aQ54 mice were 
produced by crossing B6.Q54 hemizygous transgenic males with SJL/J females.  Scn1a+/- 
mice were generated as previously described and are maintained as a congenic line on the 
129S6/SvEvTac background (129.Scn1a+/-).43  For experiments, F1 generation Scn1a+/- 
mice were produced by crossing 129.Scn1a+/- mice with C57BL/6J mice.  Mice were tail 
biopsied in the second postnatal week, and DNA was prepared from tail tissue using 
Gentra Puregene Mouse Tail kit according to the manufacturer’s instructions (Qiagen, 
Valencia, CA).  Genotyping of the Scn2aQ54 transgene was performed as previously 
described.41 Genotyping of Scn1a+/- mice was performed as previously described.43  
Experimental animals used in this study were age 30-35 days unless otherwise noted.   
 
Drugs and compounds 
Ranolazine dihydrochloride (Sigma-Aldrich, St. Louis, MO, USA), phenytoin sodium 
injection, USP (Baxter Healthcare, Corp., Deerfield, IL, USA), phenytoin (Sigma-
Aldrich, St. Louis, MO, USA) and GS967 (Gilead Sciences, Foster City, CA, USA) were 
used.  For electrophysiological experiments, phenytoin and GS967 were prepared at stock 
concentrations of 50 mM and 10 mM respectively in DMSO, and diluted in the 
appropriate bath solution at the time of recording. The final DMSO concentration was 
always less than 0.02%.  A solution of ranolazine was prepared in Dulbecco’s phosphate 
buffered saline (PBS) with pH readjusted to 7.1. Drug-free PBS was used as a vehicle 
control for ranolazine experiments.  Phenytoin sodium was diluted in 0.5% methyl 
cellulose, and the vehicle control solution contained 10% ethyl alcohol, 40% propylene 
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glycol and 50% water diluted in 0.5% methyl cellulose.  The pH of phenytoin and vehicle 
solutions was between 7.5 and 8.0. A solution of GS967 was prepared in a vehicle 
solution containing 15% NMP, 10% solutol HS-15 and 75% water for MES experiments.  
GS967 was formulated in Purina 5LOD chow at concentrations of 2 mg/kg and 8 mg/kg 
by Research Diets, Inc. for experiments involving Scn2aQ54 and Scn1a+/- mice. 
 
In vivo pharmacology 
Non-transgenic F1 wildtype (C57BL/6J x SJL/J) mice purchased from The Jackson 
Laboratory (Bar Harbor, ME, USA) were used to study ranolazine pharmacokinetics in 
vivo.  Ranolazine (40 mg/kg) was administered as a single intraperitoneal (i.p.) injection 
in a volume of 10 ml/kg body weight.  At selected time points (10, 20, 30 or 40 minutes), 
four animals per group were deeply anesthetized before collecting blood and brain 
samples. Blood and brain samples were also collected from the phenytoin and GS967 
experimental animals. Plasma was isolated by centrifugation (9000 x g, 10 minutes).  
Brain tissue was homogenized in 3% sodium fluoride solution containing 1% HCl (300 
mg tissue in 600 µl).  Ranolazine and GS967 concentrations were measured by liquid 
chromatography coupled with tandem mass spectrometry as previously described.61  
Plasma phenytoin concentration was assayed by Vanderbilt University Medical Center 
Core Chemistry Laboratory using fluorescence polarization immunoassay technology 
(COBAS INTEGRA; Roche, Basel, Switzerland). 
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Acute isolation of hippocampal neurons 
Electrophysiology experiments were performed on acutely dissociated hippocampal 
pyramidal neurons isolated from Scn2aQ54 mice.  Mice were anesthetized with isoflurane 
and brains were removed under aseptic conditions. Slices (400 µm) were obtained using a 
Leica VT1200 microtome (Leica Microsystems, Nussloch, Germany). The hippocampus 
was isolated by dissection in ice cold sterile filtered dissection solution (in mM: 110 
NaCl, 2.5 KCl, 7.5 MgCl2, 10 HEPES, 75 sucrose, 25 glucose, pH 7.4), then allowed to 
recover in ACSF solution containing (in mM: 124 NaCl, 4.4 KCl, 2.4 CaCl2, 1.3 MgSO4, 
1 NaH2PO4, 10 glucose, and 26 NaHCO3, pH 7.35) for a period of 1-6 hours.  Neurons 
were dissociated by protease XXIII digestion (1.5 mg/ml) at room temperature in a 
solution containing (in mM: 82 Na2SO4, 30 K2SO4, 5 MgCl2, 10 HEPES, 10 glucose, pH 
7.4). Cells were triturated in dissociation solution containing 1 mg/ml bovine serum 
albumin, then placed in recording solution for electrophysiological experiments.65 
 
Electrophysiology 
Mutagenesis of recombinant rat NaV1.2 (rNaV1.2) was performed as described 
previously.26,66,67  Three mutations (G879Q, A880Q, L881Q) were introduced into full 
length rNaV1.2 to recapitulate the Scn2aQ54 transgene. Heterologous expression of 
rNaV1.2 in tsA201 cells and whole cell voltage clamp recording were performed as 
previously described.68  Persistent sodium current was measured during the final 10 ms of 
a 200 ms depolarization to 10 mV from a holding potential of 120 mV in the absence 
and presence of 1 µM GS967 or 10 µM phenytoin, followed by application of 0.5 µM 
tetrodotoxin (TTX) and offline digital subtraction as described previously.68  Use-
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dependent rundown was measured at stimulation frequencies of 10, 30, and 100 Hz in the 
absence and presence of either 1 µM GS967 or 10 µM phenytoin, followed by 
application of 0.5 µM TTX and offline digital subtraction of TTX-resistant current.  
Whole cell recordings of neuronal cell bodies were made in current clamp mode using an 
Axon MultiClamp 700B amplifier. Patch pipettes were fabricated from borosilicate glass 
using a multistage P-97 Flaming Brown micropipette puller (Sutter Instruments, Novato, 
CA), and fire-polished using a microforge (Narishige, Japan). Final pipette resistance was 
2.0 – 2.5 MΩ when filled with a solution containing (in mM: 110 K-gluconate, 10 KCl, 
10 HEPES, 10 dextrose, 10 sucrose, 10 phosphocreatine-Na2, 5 EGTA, 4 Mg-ATP, 0.3 
Na-GTP, 0.1 CaCl2, pH 7.35, 300 mOsmol/kg).  Bath solution consisted of (in mM: 155 
NaCl, 3.5 KCl, 1 MgCl2, 1.5 CaCl2, 10 HEPES, pH 7.35). The reference electrode 
consisted of a 2% agar bridge with composition of the bath solution. All whole-cell 
recordings were low-pass Bessel filtered at 5 kHz and digitized at 50 kHz. Membrane 
potential was clamped to 80 mV and cells were allowed to fire spontaneously. 
Spontaneous action potential firing frequency was measured in the absence and presence 
of GS967 (100, 300 and 1000 nM). Statistical comparisons were made using either 
Student’s t-test or one-way ANOVA followed by Tukey’s post-test and p < 0.05 was 
considered statistically significant.   
 
Evaluation of anti-seizure activity in Scn2aQ54 mice 
Anti-seizure activity was evaluated by comparing the number of behavioral seizures 
captured by video recording during a 30-min pre-treatment period with the number 
occurring during a 30-min post-drug period in male Scn2aQ54 mice.  Behavioral seizures 
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(tonic deviation of the head and body accompanied by forelimb clonus) were previously 
correlated with electroencephalographic seizures using video-EEG monitoring, and work 
in our laboratory has shown strong agreement between detection of seizures using 
behavioral and electroencephalographic observations (kappa 0.988) in untreated mice.40  
Mice were implanted with prefabricated headmounts (Pinnacle Technology, Inc., 
Lawrence, KS, USA) for video-EEG monitoring as previously described.52Video-EEG 
data was collected from ranolazine treated mice. Mice were placed in individual clear 
Plexiglas recording cages for 60-min prior to drug treatment (30-min habituation 
followed by the 30-min pre-treatment period). Drug treatments were randomly assigned 
within experimental groups.  Mice received 40 mg/kg ranolazine (maximum tolerated 
dose) or PBS as a single i.p. injection and were immediately returned to the recording 
cage for the 30-min post-treatment period.  Phenytoin experimental animals received a 
single i.p. injection of either 30 mg/kg phenytoin, which produced a plasma concentration 
within the human therapeutic range, or vehicle and were returned to the home cage for a 
delay of 75-min.  Mice were then placed into the recording cage for 30-min habituation 
followed by the 30-min post-treatment period.  The delay between drug injection and 
post-treatment period for each drug was based upon the time to peak plasma ranolazine 
concentration and the previously determined time to peak phenytoin effect.69  For both 
ranolazine and phenytoin experiments, digital video images captured during the two 30-
min video-monitored periods (pre- and post-drug treatment) were analyzed offline by two 
independent observers blinded to treatment. Statistical comparisons were made using 
repeated measures ANOVA and p < 0.05 was considered statistically significant.   
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GS967 could not be administered satisfactorily by the i.p. route because the vehicle alone 
caused excessive sedation in mice, and the stress of intravenous or oral gavage 
administration would have exacerbated seizures in Scn2aQ54 mice.  Therefore, GS967 was 
administered orally through supplementation in chow.  Baseline seizure frequency was 
quantified for 30 minutes in the GS967 experimental group (pre-treatment period), then 
mice were returned to the home cage and received either control or GS967 containing 
chow (either 2 mg drug per kg chow or 8 mg drug per kg chow; dosage estimated as 
0.375 mg/kg/d and 1.5 mg/kg/d, respectively, based on the consumption of 3.5-4 g chow 
per day).  Seizures were quantified offline by two independent observers blinded to 
treatment for 30 minutes at 24 and 48 hours after onset of treatment (post-treatment 
period), and percent change in seizure frequency was calculated. Statistical comparisons 
were made using repeated measures ANOVA and p < 0.05 was considered statistically 
significant.   
 
Maximal electroshock-induced seizures 
MES experiments were performed at The Jackson Laboratory (Bar Harbor, ME, USA) 
using 9 week old C57BL/6J male mice.  Mice were administered either GS967 or 
phenytoin solutions by oral gavage in a volume of 10 ml/kg body weight 2 hours prior to 
MES testing.  All tests were conducted at the empirically determined time to peak GS967 
and previously determined time to peak phenytoin effect.69  Transcorneal electrodes were 
placed on anesthetized corneas (0.5% tetracaine in normal saline). Electrical stimuli (20.5 
mA, 299 Hz, 1.6 ms pulse width, constant current previously determined to be the critical 
current for 97% of C57BL/6J animals to experience tonic hindlimb extension  was 
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delivered for 0.2s using the Ugo Basile (Model 7800) electroconvulsive device (Stoelting 
Co., Wood Dale, IL, USA).70  Maximal seizures appear as a tonic-clonic 
flexion/extension sequence, beginning with tonic extension of the forelimbs and 
terminating with tonic hindlimb extension.  Maximal seizures were scored with full tonic 
hindlimb extension (hindlimbs at 180 degree angle to the torso) as the endpoint.  Probit 
analysis was used to determine ED50 values (concentration required to protect 50% of 
animals against MES-induced seizures) for GS967 and phenytoin. 
 
Survival Analysis 
At weaning (postnatal day 21), Scn2aQ54 mice were randomly assigned to either GS967 
or control treatment groups.  Survival was monitored until 12 weeks of age.  Scn1a+/- 
mice were weaned at postnatal day 18 and randomly assigned to either GS967 or control 
treatment groups.  Survival was monitored until 8 weeks of age.  Animals in the GS967 
treatment group were provided chow containing GS967 (8 mg/kg). Statistical 
comparisons were made using the Cox proportional hazards model and p < 0.05 was 
considered statistically significant. 
 
Histology 
Cresyl Violet and Timm staining were used to detect hilar neuron loss and mossy fiber 
sprouting, respectively, in the dentate gyrus of female mice (age 60-65 days).  At 
weaning (postnatal day 21), Scn2aQ54 mice or wildtype (WT) littermates were randomly 
assigned to either GS967 or control treatment groups. Animals in the GS967 
experimental group were provided chow containing GS967 (8 mg/kg) until morning of 
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sacrifice.  Mice in both treatment groups underwent 30 minutes of video-taped 
observation just before sacrifice.  Seizure frequency was quantified by offline analysis of 
the video recordings by an observer blinded to treatment.  Staining with Cresyl Violet 
was performed as previously described.40  Timm staining was performed as previously 
described.71  Mossy fiber sprouting was measured by quantifying the density of stain 
within the inner molecular layer of the dentate gyrus from both the suprapyramidal and 
infrapyramidal blades.  An image of the dentate gyrus was obtained with a 10x objective 
from 2 sections from each mouse.  NIH ImageJ was used to acquire a total of 6 density 
measurements from each section (12 measurements per mouse).  Each measurement was 
normalized to the background staining within the outer molecular layer of the section 
(Figure 3.1).  These values were averaged to obtain a single density measurement for 
each animal.  Mossy fiber sprouting was compared among groups using one-way 
ANOVA followed by Tukey HSD post-hoc tests and p < 0.05 was considered statistically 
significant.  Statistical analysis was conducted using STATA 12.0 (StataCorp LP, College 
Station, TX).  
 
 
 
 
Figure 3.1. Quantification strategy for mossy fiber sprouting.  NIH ImageJ was used to 
perform densitometry within the granular layer of the dentate gyrus.  Density measurements 
were made within the inner molecular layer of the dentate gyrus from both the suprapyramidal 
and infrapyramidal blades (red circles).  Each measurement was normalized to the average 
background staining within the outer molecular layer of the section (yellow circles).  Areas 
measured were circles with a radius of 0.36 inches.      
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RESULTS 
Ranolazine reduces seizure frequency in Scn2aQ54 mice 
Previous work in heterologous cells demonstrated that ranolazine preferentially 
suppressed persistent sodium current induced by several human NaV1.1 mutants.72  Here 
we tested the ability of ranolazine to reduce seizure frequency in vivo using Scn2aQ54 
mice that have seizures as a consequence of an abnormal neuronal persistent sodium 
current conducted by a mutant NaV1.2 transgene.  Seizure frequency was quantified for 
30 minutes before and after intraperitoneal administration of 40 mg/kg ranolazine or 
vehicle.  Ranolazine reduced seizure frequency significantly compared to vehicle treated 
animals (Figure 3.2).  Additionally, a subset of animals (n=9) were monitored with 
simultaneous video-EEG recording. Following acute ranolazine treatment, we found a 
98% correlation between electroencephalographic and behavioral seizures (55 behavioral 
vs 56 electroencephalographic) and this was not different from untreated animals. The 
proportional reduction in seizure frequency was modest (48%) possibly due to short 
plasma half-life (~15 minutes) and low brain penetration of ranolazine in mice (Table 
3.1).  Despite the pharmacokinetic limitations of ranolazine, these results provided a 
proof-of-principle that preferential suppression of persistent sodium current can exert an 
antiepileptic effect.  
Table 3.1.  
Plasma and brain concentrations     
Drug* 
Dosage 
(mg/kg)** 
% Change in 
Seizure Frequency [Plasma]†  [Brain]  
Ranolazine 40 -48 ± 10% 19.3 ± 0.8 µM 4.9 ± 0.1 µM 
Phenytoin 30 -93 ± 5% 87.2 ± 1.2 µM  ND 
GS967 1.5 -92 ± 4% 0.6 ± 0.1 µM 0.6 ± 0.2 µM 
     
 
 
*Ranolazine and phenytoin were administered as single i.p. injections.  GS967 was orally 
administered through supplementation in chow. **, GS967 dose is in units of mg/kg/day; 
†phenytoin and GS967 are both highly (>90%) protein bound in plasma; ND, not determined 
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GS967 inhibits persistent current and spontaneous action potential firing 
The  novel compound, GS967, has recently been shown to selectively inhibit persistent 
sodium current mediated by the cardiac voltage gated sodium channel with much greater 
potency than ranolazine and has no cross reactivity with over 600 other molecular targets 
at 1 µM concentration.63  To investigate the effects of GS967 on brain NaV channels, we 
performed whole-cell voltage clamp recordings on tsA201 cells expressing a mutant 
NaV1.2 cDNA derived from the Scn2aQ54 transgene (NaV1.2-GAL879-881QQQ). 
External application of GS967 suppressed persistent sodium current with an estimated 
IC50 of 0.44 ± 0.16 µM, while peak (transient) current was inhibited with an estimated 
IC50 of 18.7 ± 47.2 µM (solubility limits of GS967 precluded testing concentration higher 
than 10 M) indicating a 42-fold greater preference for persistent current block over peak 
current block (p < 0.05; Figure 3.3 A,C). For comparison, phenytoin, a commonly 
prescribed AED, also inhibited persistent current (IC50 of 15.9 ± 24.7 µM vs. IC50 of 
Figure 3.2. Ranolazine reduces seizure frequency in Scn2aQ54 mice.  (A) Number of seizures 
for individual male mice before and after treatment of either vehicle (left) or ranolazine 
(right).  (B) A histogram of percent change in seizure frequency following a single i.p. 
injection of either vehicle or ranolazine (40 mg/kg).  Percent change was calculated in 
response to treatment, with n = 9 for each treatment (**p < 0.005; repeated measures 
ANOVA). 
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143.7 ± 70.1 µM, p < 0.05; Figure 3.3 B,C), but with lower potency and less preference 
(9-fold) over peak compared to GS967. Additionally, application of 1 µM GS967 induces 
small hyperpolarized shifts in the voltage dependence of activation and steady-state 
inactivation, and slows the fast component of recovery from fast inactivation  (Figure 3.4, 
Table 3.2).  A common feature of several AEDs is use-dependent inhibition of transient 
sodium current. Therefore, we examined use-dependent inhibition of NaV1.2-GAL879-
881QQQ mediated sodium current by either 1 µM GS967 or 10 µM phenytoin at 
different frequencies (10 – 100 Hz). We observed minimal steady-state use-dependent 
inhibition by GS967 across the range of stimulation frequencies (Figure 3.3 D), 
consistent with the activity of this drug observed on the cardiac voltage gated sodium 
channel.63  However, as expected, phenytoin exhibited strong use-dependent block of 
transient sodium current (Figure  3.3 D), with a greater degree of inhibition at high 
stimulation frequencies (44.2 ± 3.7%) compared to low frequency stimulation (22.6 ± 
2.8%, p < 0.05). These data suggest that GS967 acts mainly through a tonic block 
mechanism to preferentially inhibit persistent sodium current.  
 
Table 3.2.           
Effect of GS967 on Nav1.2-GAL978-881QQQ Biophysical Properties 
Voltage Dependence         
of Activation 
Voltage Dependence of Fast 
Inactivation Recovery from Fast Inactivation 
V1/2  (mV) k (mV) V1/2  (mV) k (mV) τf (ms) τs (ms)
Control -15.2 ± 0.8 8.5 ± 0.2 -67.5 ± 1.4 -5.4 ± 0.1 7.3 ± 0.5 (84 ± 2%) 572.1 ± 81.6 (17 ± 4%) 
GS967 -18.1 ± 0.9* 8.6 ± 0.2 -71.1 ± 1.6* -5.5 ± 0.2 15.2 ± 3.2* (40 ± 5%*) 78.9 ± 8.5* (56 ± 4%*) 
*p < 0.05 compared to control conditions, with n = 9-15 per condition 
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Figure 3.3.  GS967 inhibits persistent sodium current. (A) Representative trace of sodium 
current in the absence (black trace) or presence (red trace) of 1 M GS967. The inset 
illustrates persistent sodium current on an expanded scale. (B) Representative trace of voltage 
dependent sodium current in the absence (black trace) or presence (blue trace) of 10 M 
phenytoin. The inset illustrates persistent sodium current on an expanded scale. (C) 
Concentration response inhibition of persistent sodium current (closed symbols, solid lines) 
and transient sodium current (open symbols, dashed lines) by GS967 (red circles) and 
phenytoin (blue squares). (D) Steady-state use-dependent inhibition of transient sodium 
current by either 1 M GS967 (red symbols) or 10 M phenytoin (blue symbols) at 
stimulation frequencies of 10, 30, or 100 Hz. Values represent ratios of use-dependent 
inhibition in the presence of drug to that in the absence of drug. All data are expressed as 
mean ± SEM, with n = 7-11 for each condition – Chris Thompson, PhD. 
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We next investigated whether GS967 could exert preferential suppression of persistent 
sodium current in neurons isolated from Scn2aQ54 mice and whether this effect would 
inhibit neuronal action potential firing. Persistent current measurements from 
hippocampal pyramidal neurons isolated from Scn2aQ54 mice demonstrated that 1 µM 
GS967 significantly reduced persistent current from 1.2 ± 0.4% of peak current amplitude 
(n = 8) measured under control conditions to 0.1 ± 0.1% (n = 5, p < 0.05; Figure 3.5 
A,B). Whole-cell current clamp recording was then performed on hippocampal pyramidal 
Voltage (mV) 
Figure 3.4.  Effect of GS967 on NaV1.2-GAL879-881QQQ biophysical properties. (A) Peak 
current density elicited by test pulses to various membrane potentials and normalized to cell 
capacitance. (B) Voltage dependence of channel activation measured between 80 to +20mV 
(C) Voltage dependence of inactivation measured following a 100 ms inactivating prepulse 
ranging from 140 to 10 mV. (D) Time-dependent recovery from inactivation assessed with 
a 100 ms inactivating prepulse to 10 mV. Black symbols represent data recorded under 
control conditions while blue symbols are data recorded in the presence of 1 M GS967. Data 
are represented as mean ± S.E.M., with n = 9 – 11 for each condition  – Chris Thompson, 
PhD. 
 
Recovery Interval (ms) 
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neurons in the presence and absence of GS967. Neurons isolated from Scn2aQ54 mice 
exhibited high frequency spontaneous action potential firing, unlike wildtype littermates 
that exhibit rare spontaneous firing (Figure 3.5 C). Application of 1 µM GS967 reduced 
firing frequency by 98.8 ± 0.1% (n = 7) and this effect was reversible upon washout of 
the compound. Suppression of neuronal firing by GS967 was concentration-dependent, 
with an estimated IC50 of ~250 nM (Figure 3.5 D). By comparison, 1 µM phenytoin 
inhibited spontaneous action potential firing by only 36.7 ± 10.1% (open square in Figure 
3.5 D). 
 
Based on these in vitro observations coupled with the ability of GS967 to effectively 
cross the blood-brain barrier (Table 3.1), and a slower rate of elimination than ranolazine, 
we hypothesized that GS967 would exert antiepileptic activity in vivo. Accordingly, we 
examined the effect of GS967 in vivo using three distinct mouse models of epilepsy. 
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Figure 3.5. GS967 inhibits persistent current and spontaneous firing in Scn2aQ54 neurons. (A) 
Representative normalized trace of sodium currents from hippocampal pyramidal neurons 
from Scn2aQ54 (F1.Q54) mice recorded in the absence (black trace) or presence (red trace) of 1 
µM GS967. (B) Summary data for persistent sodium current (expressed as % of peak current) 
recorded from pyramidal neurons in the absence or presence of 1 µM GS967. Peak current 
densities were not significantly different between control and GS967 conditions (control: 
187.2 ± 32.6 pA/pF; GS967: 172.3 ± 46.2 pA/pF).  (C) Representative spontaneous action 
potential firing recorded from a hippocampal pyramidal neuron from either wildtype (F1.WT) 
or Scn2aQ54 (F1.Q54) mice. Membrane potential was clamped at 80 mV and spontaneous 
action potentials were recorded in the absence and presence of 1 µM GS967. (D) 
Concentration response of inhibition of spontaneous action potential firing by GS967 (closed 
circles) and inhibition action potential firing by 1 µM phenytoin (open square). Data are 
expressed as mean ± SEM, with n = 5-7 for each concentration (* p < 0.05) – Chris 
Thompson, PhD. 
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Seizure frequency in Scn2aQ54 mice is reduced by GS967 
We tested the ability of short-course (1-2 days) oral GS967 to reduce seizure frequency in 
Scn2aQ54 mice.  Mice maintained on 0.375 mg/kg/d GS967 exhibited a 50% reduction in 
seizure frequency whereas mice treated with higher dose (1.5 mg/kg/d) GS967 exhibited 
more than 90% seizure reduction following two days of treatment (Figure 3.6). The 
efficacy of this compound to suppress seizures in Scn2aQ54 mice is similar to phenytoin 
(30 mg/kg), but the anticonvulsant effect of GS967 requires a much lower plasma 
concentration (Table 3.1). Vehicle controls for both GS967 and phenytoin treated animals 
exhibited no reduction in seizure frequency.  It was observed that mice treated with 
phenytoin exhibited sedation characterized by lack of ambulation. Although there was a 
trend toward sedation, it was not significantly different from vehicle treated mice (5/7 
awake for vehicle vs. 3/8 awake for phenytoin, p = 0.31).  By contrast, no sedation was 
observed in GS967 and respective control treated animals.   
 
 
 
 
 
Figure 3.6.  GS967 reduces seizure frequency in Scn2aQ54 mice.  (A) Number of seizures in 
30 minutes for individual mice at baseline (day 0) and after treatment (day 1 and 2) with either 
control chow or 1.5 mg/kg/d GS967.  (B) A histogram of percent change in seizure frequency 
following oral administration of either control or chow containing GS967 at two dosage 
levels.  Percent change was calculated in response to treatment, with n = 6 for each treatment  
(*p < 0.05 and **p < 0.005 compared to control; repeated measures ANOVA). 
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GS967 suppresses MES-induced seizures 
To further investigate the antiepileptic activity of GS967, we tested the ability of the 
compound to prevent MES-induced generalized tonic hindlimb seizures in wildtype 
C57BL/6J mice. Varying dosages of GS967 that yielded 0 to 100% protection were orally 
administered two hours prior to testing.  Protection of MES-induced tonic hindlimb 
extension by GS967 was dose-dependent (Figure 3.7), with a calculated ED50 value of 0.1 
mg/kg. Vehicle treatment exhibited no protection against MES-induced seizures. For 
comparison, we experimentally determined an ED50 value of ~5 mg/kg for phenytoin 
protection against MES-induced tonic hindlimb extension consistent with previously 
published data.69  These observations indicate that GS967 has antiepileptic activity in two 
mechanistically divergent models of epilepsy. 
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Figure 3.7.  GS967 protects against MES-induced seizures.  Dose response curve for seizure 
protection by GS967. Data are shown as percentage of animals protected from seizure at a 
given dose of drug, with n = 5-8 animals per dose. In collaboration with Wayne Frankel, PhD 
at The Jackson Laboratory. 
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GS967 improves survival of Scn2aQ54 mice 
Scn2aQ54 mice have a significantly reduced lifespan with approximately 20% surviving to 
12 weeks of age (Figure 3.8).  Poor survival of Scn2aQ54 mice has been attributed to 
chronic, unrelenting seizures with widespread neuronal injury.  We tested whether 
preferential suppression of persistent current by GS967 would increase the lifespan of 
Scn2aQ54 mice.  Mice were continuously treated with GS967 beginning at postnatal day 
21 and survival was monitored until 12 weeks of age. GS967 treatment dramatically 
improved the survival of Scn2aQ54 mice with 90% of mice alive at 12 weeks compared to 
20% survival of control (untreated) animals (p < 0.005; Figure 3.8). 
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Figure 3.8.  GS967 improves survival of Scn2aQ54 mice.  Survival curves of Scn2aQ54 mice 
placed on control chow or chow containing GS967 (dose 1.5 mg/kg/d). Treatment began at 3 
weeks of age indicated by the dashed line, with n = 18-20 per group. Survival difference 
between groups was significant at p < 0.005; Cox proportional hazards model.  
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Survival of Scn1a+/- mice improved by GS967 
Scn1a+/- mice have a significantly reduced lifespan with only ~30% survival to 8 weeks 
of age (Figure 3.9).  Poor survival of Scn1a+/- mice has been attributed to seizure clusters 
in a developmentally sensitive time window around the time of weaning.  The seizures 
result from impaired GABA-mediated inhibition due to haploinsufficiency of SCN1A.  
We tested whether inhibition of persistent sodium current by GS967 would further impair 
GABA-mediated inhibition thereby exacerbating the phenotype of Scn1a+/- mice.  
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GS967 treatment prevents hilar neuron loss in Scn2aQ54 mice 
Widespread neuronal loss in the dentate hilus is a commonly observed histopathological 
change in epilepsy patients and animal models of epilepsy, including the Scn2aQ54 mouse 
model.40,73,74  We investigated whether chronic GS967 treatment would prevent neuron 
loss in Scn2aQ54 mice.  Cresyl Violet staining revealed extensive neuronal cell loss in the 
Figure 3.9.  GS967 improves survival of Scn1a+/- mice.  Survival curves of Scn1a+/- mice 
placed on control chow or chow containing GS967 (dose 1.5 mg/kg/d). Treatment began at 18 
days of age indicated by the dashed line, with n = 12-13 per group. Survival difference 
between groups was significant at p < 0.005; Cox proportional hazards model.  
 
52 
 
dentate hilus in 60 day-old Scn2aQ54 mice compared to age-matched wildtype (WT) 
littermates (Figure 3.10) as reported previously.40  By contrast, qualitatively, there was no 
overt hilar neuron loss in GS967 treated Scn2aQ54 mice, indicating that GS967 treatment 
provides a neuronal preservation effect possibly by attenuating excitotoxicity caused by 
persistent sodium current. 
 
 
 
 
 
 
Mossy fiber sprouting is suppressed by GS967 treatment 
Seizure-induced sprouting of the mossy fiber pathway in the dentate gyrus is a frequently 
observed morphological change associated with epilepsy and has also been observed in 
Scn2aQ54 mice.40,74  We tested whether chronic GS967 treatment of Scn2aQ54 mice would 
Figure 3.10.  GS967 prevents hilar neuron loss in Scn2aQ54 mice. A-C, Cresyl violet stained 
sections of the dentate gyrus from a representative wildtype mouse (WT, panel A), untreated 
Scn2aQ54 mouse (F1.Q54, panel B) and a Scn2aQ54 mouse treated with 1.5 mg/kg/d GS967 
from age P21 to P60 (F1.Q54 + GS967, panel C).  Images in the middle and lower panels are 
high-magnification views. Scale bars represent 500 µm, 200 µm and 100 µm for the upper, 
middle and lower panels, respectively.  
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attenuate mossy fiber sprouting. Using Timm staining, we observed evidence of robust 
mossy fiber sprouting within the inner molecular layer of the dentate gyrus in 60 day-old 
Scn2aQ54 mice compared to age-matched WT littermates (Figure 3.11 A,B).  By contrast, 
Scn2aQ54 mice chronically treated with GS967 exhibited a low density of Timm staining 
(Figure 3.11).  Mossy fiber sprouting was quantified in the inner molecular layer of the 
dentate gyrus using densitometry normalized to background staining.  There was a 
significant (p < 0.05) reduction in the extent of mossy fiber sprouting in GS967 treated 
Scn2aQ54 mice (1.32 ± 0.12) compared to untreated Scn2aQ54 (1.81 ± 0.16*) and WT (1.36 
± 0.07) animals.  These findings indicate that chronic seizure suppression by GS967 
suppressed mossy fiber sprouting in Scn2aQ54 mice. 
 
 
 
 
 
 
 
Figure 3.11.  GS967 suppresses mossy fiber sprouting in Scn2aQ54 mice. A-C, Timm stained 
sections of the dentate gyrus from a wildtype (WT, panel A) untreated Scn2aQ54 mouse 
(F1.Q54, panel B) and a Scn2aQ54 mouse treated with GS967 from age P21 to P60 (F1.Q54 + 
GS967, panel C).  Images in the lower panels are high-magnification views. Scale bars 
represent 500 µm and 200 µm for the upper and lower panels, respectively. Quantification of 
the average density in the inner molecular layer of the dentate gyrus normalized to 
background is reported below images.  Data are expressed as mean ± SEM, with n = 6-8 per 
group (*p < 0.05; one-way ANOVA followed by Tukey HSD post-hoc). 
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DISCUSSION 
In this study, we determined the anticonvulsant effect of ranolazine and GS967, two 
persistent sodium current blockers. AEDs targeting voltage-gated sodium channels have 
existed for many years, and most exert their clinical effects through use-dependent block 
of transient sodium current in a manner similar to that of local anesthetics. Use-dependent 
block of the transient sodium current can dampen neuronal excitability especially during 
rapid firing such as the hypersynchronous bursts associated with seizures. While some 
AEDs may also suppress persistent sodium current to some extent, no currently approved 
AED has a strong preference blocking this activity.75  
 
Persistent sodium current and epilepsy 
Under normal physiological conditions, opening of voltage-gated sodium channels is 
short-lived and lasts only a few milliseconds before the process of fast inactivation 
returns current levels to near baseline values.  However, a small amount of sodium 
current may persist after the main transient current is extinguished. This persistent 
sodium current can influence neuronal firing by amplifying subthreshold synaptic inputs 
or evoking a sustained membrane depolarization.59  The ability of persistent sodium 
current to promote neuronal excitability has led to speculation that this current may 
contribute to epilepsy possibly by allowing pathological firing frequencies or by enabling 
the spread of epileptic neuronal activity.  
 
Several lines of evidence support the hypothesis that persistent sodium current can be 
epileptogenic. Mutations in human NaV1.1, NaV1.2, NaV1.3 and NaV1.6 sodium channels 
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have been associated with a spectrum of genetic epilepsies. In vitro experiments probing 
the functional consequences of several human mutations have revealed increased 
persistent sodium current as a major, and sometimes solitary, defect.26,66,76-79  Further, 
low level expression of a mutant NaV1.2 transgene exhibiting increased persistent current 
in the Scn2aQ54 mouse model demonstrates the pathogenic nature of this current.40  
Additionally, Chen and colleagues demonstrated high-threshold bursting in hippocampal 
CA1 neurons is driven by persistent sodium current in the pilocarpine-induced status 
epilepticus rat model of temporal lobe epilepsy.80  The authors speculate that increased 
persistent sodium current contributes to establishing chronic epilepsy in this rodent 
model.  More recently, evidence from Drosophila demonstrate important contributions of 
persistent neuronal sodium current to seizure phenotypes arising from spontaneous and 
engineered mutants.81,82   While increased persistent current does not account for all 
genetic epilepsies arising from mutant sodium channels, this mechanism appears to be an 
important contributor in many situations.  
 
Anticonvulsant activity of GS967 
GS967 has previously been shown to preferentially inhibit persistent sodium current 
mediated by the cardiac voltage gated sodium channel and is an effective suppressor of 
ventricular arrhythmias.63,64  Unlike ranolazine, GS967 is capable of effectively 
penetrating the blood brain barrier and has slow elimination from the body, suggesting 
that this compound may have more efficacious antiepileptic activity. Our data show that 
GS967 was capable of preferentially suppressing persistent sodium current mediated by a 
neuronal voltage-gated sodium channel with greater potency than the commonly 
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prescribed AED phenytoin, and inhibited spontaneous action potentials in pyramidal 
neurons isolated from Scn2aQ54 mice.  Importantly, GS967 suppressed seizures in both 
the MES-induced seizure model and the Scn2aQ54 mouse model of epilepsy.  
 
Many Dravet syndrome patients treated with sodium channel blockers such as 
lamotrigine show no benefit, and in some cases, experience worsening epilepsy.58  
Therefore, we hypothesized that because GS967 selectively inhibits voltage-gated sodium 
channels, Scn1a+/- mice would be refractory to GS967 treatment.  Surprisingly, however, 
GS967 treatment significantly improved the lifespan of Scn1a+/- mice.  Initial studies 
suggested that Dravet syndrome stemmed from a loss of GABAergic inhibitory tone.  
However, more recent studies have shown that in addition to impaired GABA-mediated 
inhibition, the mechanism responsible for Dravet syndrome may also involve a 
hyperexcitable component resulting from hyperactive pyramidal neurons.  Specifically, 
pyramidal neurons isolated from Scn1a+/- mice showed an increased sodium current 
density and a hyperpolarizing shift in the voltage-dependence of activation compared to 
wildtype animals which is consistent with hyperexcitability.44  Additionally, 
differentiated pyramidal neurons derived from Dravet syndrome patient iPSCs exhibit 
increased sodium current density and hyperexcitability.55  We propose that GS967 
prolongs the lifespan of Scn1a+/- mice by inhibiting the abnormal voltage-gated sodium 
current observed in hippocampal pyramidal neurons, thereby reducing overall 
excitability.        
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GS967 suppresses mossy fiber sprouting 
Mossy fiber sprouting refers to the aberrant growth of granule cell axons (mossy fibers) 
into the inner molecular layer of the dentate gyrus.74  This phenomenon has been 
observed in patients with epileptic seizures and in animal models of epilepsy, but the 
contribution of mossy fiber sprouting to epileptogenesis remains unclear and 
controversial.  Substantial evidence supports the idea that the sprouted fibers form 
synapses on granule cells and generate recurrent excitatory circuits capable of 
perpetuating seizure activity.74  Attempts to inhibit mossy fiber sprouting using 
commonly prescribed AEDs, including the voltage-gated sodium channel inhibitor 
lamotrigine, have been largely unsuccessful.83-86  Inhibition of the mammalian target of 
rapamycin (mTOR) signaling pathway has been demonstrated to suppress mossy fiber 
sprouting in animal models of temporal lobe epilepsy.87  Our results appear to represent 
the first example of a sodium channel blocking drug with anticonvulsant properties 
capable of suppressing mossy fiber sprouting in an epileptic animal model.   
 
 
CONCLUSION 
 
We demonstrated anticonvulsant activity for two preferential persistent sodium current 
blockers. We further demonstrated that GS967 is a potent and selective inhibitor of 
persistent current that suppresses seizure activity in two mouse models, dampens 
hippocampal neuronal excitability in a concentration-dependent manner, prolongs 
survival of genetic epilepsy models, and prevents both hilar neuron loss and development 
of mossy fiber sprouting in these mice. Our findings provide evidence suggesting that 
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preferential inhibition of persistent sodium current is an effective strategy for 
development of new AEDs. 
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CHAPTER IV 
 
PERSPECTIVES AND FUTURE DIRECTIONS 
 
Summary 
Epilepsy is one of the most common neurological disorders affecting approximately 50 
million people of all ages worldwide.88  Nearly two-thirds of patients diagnosed with 
epilepsy develop seizures with no obvious brain lesions or any other neurological 
abnormalities, so are presumed to be of genetic origin.1  These genetic epilepsies exhibit 
complex inheritance suggesting the involvement of multiple genes and environmental 
factors.  Recent studies, however, have identified monogenic epilepsies in which the 
syndromes arise from mutations within single genes.  All of the identified mutations 
occur in genes essential for neuronal signaling such as nicotinic acetylcholine receptors, 
GABAA receptors and voltage-gated ion channels, with mutations within voltage-gated 
sodium channels the most prevalent.17,24  Information gained from the identification and 
characterization of these mutant alleles has provided insight into the molecular 
mechanisms that underlie the pathology of epilepsy and have inspired the development of 
new therapies.   
 
The need for novel therapeutics is highlighted by the fact that 30% of epilepsy patients do 
not achieve seizure control with currently available AEDs, which creates a great burden 
both physically and socially.8  Drug resistant epilepsy represents an unmet medical 
challenge in the field that needs to be addressed and new therapies need to be developed.   
60 
 
 
Animal models of epilepsy 
While animal models have been extensively used in the past for the development and 
testing of AEDs, they may not accurately depict human epilepsy.  A definite limitation of 
these models is that they are induced seizure models rather than epilepsy models.8  
Animal models that exhibit spontaneous seizures are more etiologically relevant for 
investigating the neurophysiological basis of epilepsy and for testing new AEDs.  The 
availability of two genetic mouse models of epilepsy have provided a platform to study 
molecular mechanisms of epileptogenesis as well as a new testing ground for evaluating 
novel therapeutic strategies.  One drug that has come from such studies is GS967.  The 
compound GS967 is a potent and selective inhibitor of persistent sodium current which is 
a biophysical defect observed in association with some genetic epilepsies.  We tested the 
antiepileptic potential of GS967 and found that this compound was effective across 
multiple mouse models of epilepsy representing both gain- and loss-of-function 
phenotypes. 
 
Effectiveness of GS967 in multiple mouse models of epilepsy 
The Scn2aQ54 genetically engineered mouse model of mesial temporal lobe epilepsy 
expresses a transgene encoding a gain-of-function Nav1.2 channel.   Scn2aQ54 mice 
exhibit spontaneous seizures and premature death hypothesized to result from increased 
persistent sodium current in hippocampal neurons.40  We utilized the Scn2aQ54 mouse 
model of epilepsy to test the hypothesis that preferential inhibition of persistent sodium 
current would represent a novel antiepileptic drug mechanism.  We showed that GS967 
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reduced seizure frequency and improved survival of Scn2aQ54 mice.  These results 
indicate that GS967 is an effective AED in this genetic mouse model of epilepsy.  
Phenytoin, a conventional AED, also reduced seizure frequency in Scn2aQ54 mice, which 
validates the Scn2aQ54 model as a relevant model for testing new AEDs.  The Scn2aQ54 
mouse model represents a genetic model with spontaneous, recurrent seizures that could 
prove to be instrumental for evaluating novel compounds during AED development, 
particularly those with a target-based design strategy.   
 
We also found that GS967 was effective in the heterozygous Scn1a knockout (Scn1a+/-) 
mouse model of epilepsy.  Heterozygous deletion of Scn1a in mice models Dravet 
syndrome in human epilepsy.  Scn1a+/- mice exhibit severe, spontaneous seizures and 
premature death.  They also display a reduced threshold to induced seizures (flurothyl 
and hyperthermia) and cognitive and motor impairments.42-44  Scn1a+/- mice are excellent 
models of spontaneous genetic epilepsy that can be used to investigate mechanisms of 
epileptogenesis and exploited for AED development.  Long-term GS967 treatment 
dramatically improved the survival of Scn1a+/- mice, a result that was unanticipated.    
Initial work in Scn1a+/- mice showed reduced sodium current density and excitability in 
GABAergic interneurons leading to the interneuron-hypothesis of Dravet syndrome, 
which postulates that the loss of GABA-mediated inhibition is the underlying 
physiological mechanism of epileptogenesis.  We had hypothesized that GS967 would 
exacerbate the phenotype of Scn1a+/- mice because GS967 would further inhibit Scn1a 
which already exhibits haploinsufficiency.  Because GS967 was effective in Scn1a+/- 
mice, it suggests a more complex pathophysiology than was originally hypothesized.  
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This is consistent with recent work showing that excitatory pyramidal neuron dysfunction 
may contribute to the pathophysiology of Dravet syndrome.  Increased sodium current 
density and excitability of pyramidal neurons was recorded in both Scn1a+/- mice and 
Dravet syndrome derived iPSCs.44,55  These results postulate that Dravet syndrome may 
reflect a combination of abnormalities within interneurons and pyramidal neurons that 
create a significant imbalance in excitatory and inhibitory neurotransmission and promote 
network hyperexcitability.  Interestingly, withdrawal of GS967 at 9 weeks from a cohort 
of mice showed long-term effects as survival was maintained to 12 weeks of age.  The 
benefits of GS967 in Scn1a+/- mice that persist in the absence of drug suggest that there is 
a critical period of vulnerability in which Scn1a+/- mice are extremely susceptible to 
premature death and treatment through this period yields long-term survival.   
 
GS967 represents a novel pharmacological tool that could prove beneficial for 
investigating the neurophysiological mechanisms responsible for epileptogenesis in 
Dravet syndrome.  Additionally, GS967 may have potential as a therapeutic for Dravet 
syndrome patients.  We have shown that GS967 improves the lifespan of Scn1a+/- mice.  
The question that still remains, however, is whether GS967 can rescue the seizure 
phenotype of Scn1a+/- mice.  Scn1a+/- mice exhibit spontaneous seizure and reduced 
thresholds for flurothyl- and hyperthermia-induced seizures when compared to wildtype 
animals.  Future experiments should monitor the occurrence of spontaneous seizures and 
evaluate seizure thresholds following GS967 treatment. Electrophysiological experiments 
in hippocampal slices in the presence of GS967 would provide further insight into the 
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pathogenesis of Dravet syndrome which can be used to inform the development of novel 
therapeutics.  
 
GS967 as a novel antiepileptic drug 
The effectiveness of GS967 as an antiepileptic drug was confirmed in three 
mechanistically distinct mouse models of epilepsy.  GS967 reduced seizure frequency 
and prolonged the lifespan of Scn2aQ54 mice.  GS967 also protected against induced 
seizures in the maximal electroshock (MES) seizure model.  Phenytoin was used as a 
comparator in the Scn2aQ54 and MES models and in both cases GS967 was more potent 
at seizure suppression.  No adverse consequences were observed with GS967 treatment.  
Additionally, GS967 prevented hilar neuron loss and suppressed mossy fiber sprouting in 
Scn2aQ54 mice which appears to be the first example of a sodium channel blocking drug 
with antiepileptic properties capable of preventing mossy fiber sprouting, an added 
benefit of GS967 as an AED.  Scn1a+/- mice which model the drug refractory epileptic 
encephalopathy, Dravet syndrome, benefited from GS967 treatment.  GS967 treatment 
improved the lifespan of Scn1a+/- mice further promoting its utility as an effective AED.  
GS967 has a large therapeutic window and is selective for voltage-gated sodium channels 
as it does not affect other ion channels, transporters, receptors or kinases. The safety 
profile of GS967 coupled with its success in multiple mouse models of epilepsy certainly 
warrants consideration for a New Drug Application to move studies into higher 
organisms with the eventual goal of GS967 as a viable treatment option for epilepsy 
patients.   
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Gad67-SCN1A genetic rescue of Scn1a+/- mice 
Studies in Scn1a+/- mice have provided the field with many clues regarding the cellular 
and molecular mechanisms that contribute to the pathology of Dravet syndrome.  We 
have used the Scn1a+/- mouse model to further probe the pathophysiology of Dravet 
syndrome and to investigate potential therapies to rescue the epilepsy phenotype.  As 
described previously, we found that GS967 has AED properties in Scn1a+/- mice.  Results 
from those experiments and recent work in pyramidal neurons are suggestive of a more 
complex pathophysiological mechanism than was initially hypothesized.  The idea of a 
combination pathology for Dravet syndrome, including interneuron and pyramidal neuron 
abnormalities, is further supported by observations made in the Gad67-SCN1A transgenic 
rescue experiments. We generated three independent Gad67-SCN1A transgenic mouse 
lines selectively expressing SCN1A in GABAergic rneurons and attempted to rescue the 
Dravet syndrome phenotype of Scn1a+/- mice.  We hypothesized that if Dravet syndrome 
exhibits an interneuron-specific pathology, then restoration of SCN1A selectively in 
inhibitory neurons of Scn1a+/- mice would rescue the epilepsy phenotype.  The Gad67-
SCN1A genetic approach that we utilized was not sufficient to attenuate or prevent the 
phenotype of Scn1a+/- mice.  Additional experiments need to be performed to further 
characterize the three Gad67-SCN1A transgenic lines and will provide insight into why 
restoration of SCN1A did not alleviate the phenotype. We need to conduct experiments to 
determine the transgene integration site into the genome to ensure that our results are not 
confounded by the fact that the transgene disrupted expression of an essential gene.  We 
also need to confirm the SCN1A is localized to GABAergic neurons.  Western blot 
analysis shows varying levels of SCN1A transgene across the Gad67-SCN1A lines.  
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Future electrophysiological experiments will determine the interneuron sodium current 
density associated with each transgenic line and compare to endogenous wildtype levels.  
These experiments will inform us whether there is inadequate or excess sodium current 
restored.  It is also plausible that the epilepsy phenoptype was not rescued by the Gad67-
SCN1A transgenic strategy because the interneuron only explanation for Dravet syndrome 
is an overly simplified model, and in fact other neuronal populations may also contribute 
to the disease. 
 
Lamotrigine and Scn1a+/- :: SCN1ARC/+ mice  
We also generated two independent Gad67-SCN1A-R1648C transgenic mouse lines 
which express mutant SCN1A selectively in GABAergic neurons.  The SCN1A mutation 
R1648C has been identified in association with Dravet syndrome.29  Previous studies of 
SCN1A-R1648C demonstrated impaired cell surface trafficking, reduced sodium current 
density and increased persistent sodium current compared to wildtype channels.35,89  
Treatment of cells expressing SCN1A-R1648C with the conventional sodium channel 
inhibitors, lamotrigine and phenytoin, has shown increased cell surface expression.35  A 
paradoxical phenomenon in the treatment of Dravet syndrome is that clinically, some 
patients experience worsening seizures in response to treatment with sodium channel 
blockers such as lamotrigine.58  There are no models in which AED-induced exacerbation 
of epilepsy has been modeled and the current Dravet syndrome models do not really offer 
any explanations either.  The Gad67-SCN1A-R1648C transgenic lines provide a unique 
opportunity to examine potential mechanisms underlying exacerbation of Dravet 
syndrome by certain AEDs.  We will use the mutant transgenic mice to test the 
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hypothesis that lamotrigine treatment exaggerates the phenotype of Dravet syndrome by 
increasing cell surface expression of a dysfunctional channel.  Future experiments will 
need to evaluate the seizure phenotype of combined knockout/transgenic mice (Scn1a+/- :: 
SCN1ARC/+) following chronic lamotrigine treatment.  Additionally, in vivo experiments 
examining the effect of lamotrigine treatment on cell surface expression of SCN1A-
R1648C need to be conducted. Results from these experiments could provide a 
mechanistic basis for the adverse effects of some treatment strategies in Dravet 
syndrome.  Furthermore, Scn1a+/- :: SCN1ARC/+ mice would provide an actual model of 
spontaneous, drug-resistant epilepsy.   
 
Conclusions 
Historically, animals have been used for evaluating the safety of compounds intended for 
human use.  Advances in medical science and genetic manipulations have led to the 
generation of animal models of human diseases that have provided groundbreaking 
insight into the cellular and molecular mechanisms underlying the pathology of disease.  
Additionally, animal models have been invaluable inspiration for directing the 
development and for testing the efficacy of novel therapeutics.  The field of epilepsy is 
not excluded from the benefits surrounding the use of animal models.  Simple seizure 
models have been used for decades to screen compounds for AED discovery and identify 
potential drug candidates.  A disadvantage of these simple seizure models is that they 
model acute seizures rather than genetic epilepsy.  Genetic engineering, however, has 
enabled the generation of mouse models of epilepsy that are more etiologically relevant 
to human epilepsy.  Two distinct models have been described exhaustively throughout 
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this thesis.  The transgenic Scn2aQ54 mouse model of mesial temporal lobe epilepsy 
expresses a gain-of-function mutation in a neuronal Nav1.2 channel and exhibits 
spontaneous seizures.  While the Scn2aQ54 mouse model has been used extensively in the 
past to investigate mechanisms of epileptogenesis, we used the Scn2aQ54 model for AED 
development to test a hypothesis-driven, target-based treatment strategy.  We discovered 
that preferential persistent sodium current inhibition is an effective AED mechanism and 
GS967 was identified as a potent AED.  Since Scn2aQ54 mice are a model of epilepsy, it 
should be considered as a primary model of epilepsy to be used in future AED 
development.  The second genetic model that exhibits epilepsy is the Scn1a+/- mouse 
model, which mirrors Dravet syndrome.  The Scn1a+/- mouse model has primarily been 
used to investigate the disease mechanism of Dravet syndrome, with the goal being that 
once the pathophysiological mechanism is understood it can be converted to develop 
therapeutic strategies.  The common hypothesis responsible for the pathology of Dravet 
syndrome involves a loss of GABA-mediated inhibition due to haploinsufficiency of 
SCN1A.  Although experiments are still ongoing, we are using Scn1a+/- mice to further 
investigate the molecular basis for Dravet syndrome by utilizing a genetic approach to 
rescue the phenotype.  Results from these experiments could be used to inform 
development of target-based strategies in the treatment of Dravet syndrome.  
Serendipitously, we found that GS967 has a beneficial effect in Scn1a+/- mice, a result 
that could translate into an effective treatment strategy for Dravet syndrome.  Scn1a+/- 
mice model epilepsy and should also be used in the development of novel AEDs.   
Through the use of animal models of epilepsy, we were able to identify a novel 
compound, GS967, that shows great potential as an antiepileptic drug.  GS967 was 
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effective in three mechanistically different mouse models of epilepsy, making it a 
promising candidate for human epilepsy patients.    
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